Eric Lefkofsky Sells 250,000 Shares of Tempus AI (NASDAQ:TEM) Stock

Posted by Francis Steltz on Aug 1st, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the completion of the sale, the chief executive officer owned 200,000 shares in the company, valued at $8,412,000. This represents a 55.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM stock opened at $43.87 on Friday. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company has a fifty day simple moving average of $51.40 and a two-hundred day simple moving average of $52.70. The firm has a market capitalization of $7.88 billion, a P/E ratio of -30.47 and a beta of 3.46.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 49.56%. The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) EPS. Analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Several institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its position in shares of Tempus AI by 4.1% during the second quarter. Handelsbanken Fonder AB now owns 32,900 shares of the company’s stock valued at $1,906,000 after buying an additional 1,300 shares during the period. CoreCap Advisors LLC raised its holdings in shares of Tempus AI by 293.4% in the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock worth $59,000 after buying an additional 760 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Tempus AI by 1.3% in the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock worth $1,944,000 after buying an additional 536 shares during the period. Avidity Partners Management LP bought a new stake in shares of Tempus AI during the 1st quarter worth approximately $1,130,000. Finally, Silverback Asset Management LLC lifted its stake in shares of Tempus AI by 44.5% during the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock worth $1,614,000 after acquiring an additional 11,000 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: Q2 results beat expectations. Tempus reported an adjusted loss of $0.04 per share, narrower than the $0.14 consensus loss and improved from a $0.22 loss a year earlier. Revenue increased 21.6% year over year to $382.5 million, modestly above estimates. Tempus AI Q2 earnings report
Positive Sentiment: Management raised or reaffirmed strong 2026 growth expectations. Full-year revenue guidance is approximately $1.595 billion to $1.605 billion, supported by momentum in oncology diagnostics, data and modeling. Tempus also outlined a potential $400 million revenue uplift by 2028 tied to its xT CDx and xF products. Tempus revenue outlook
Positive Sentiment: Analyst support remains favorable. Needham reaffirmed its Buy rating and set a $75 price target, implying substantial upside from recent trading levels. Needham analyst rating
Negative Sentiment: The earnings beat did not fully resolve profitability concerns. Tempus remains unprofitable, with a negative net margin and analysts projecting a full-year loss. Revenue guidance is broadly consistent with expectations rather than a major upside surprise, contributing to the post-earnings reset. Tempus earnings call highlights
Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares. The $10.5 million sale reduced his direct holdings by more than half. Although it was conducted under a pre-arranged Rule 10b5-1 plan, the transaction can still weigh on sentiment, particularly while the stock trades well below its 52-week high. Tempus CEO stock sale

Wall Street Analyst Weigh In

TEM has been the topic of a number of recent research reports. Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of Tempus AI in a research report on Friday, July 24th. Wolfe Research assumed coverage on Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Jefferies Financial Group started coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $68.92.

Read Our Latest Research Report on Tempus AI

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.